Protein Biochip Market Evolving from Promise to Products
The protein biochip industry is shedding hype and demonstrating real value. The grandiose visions of technologies to study the entire human proteome are giving way to pragmatic divide-and-conquer approaches. This transition is driving the projected growth in the market from $122 million in 2002 to more than $500 million in 2008, according to a new report, Protein Biochips: Parallelized Screening for High-Output Biology, from BioPerspectives in San Francisco, California, Bachmann Consulting in Nesoddtangen, Norway, and the NMI Natural and Medical Sciences Institute at the University of Tübingen in Germany.
The report, written by an international team of experts (see below), has unparalleled analysis and coverage of the protein biochip market, including both planar and bead arrays. The report features a detailed discussion of the key drivers that are likely to cause major shifts in the emerging market, ranging from the content problem to the looming bottleneck in target validation to the current bottleneck in lead optimization to the enthusiasm over protein biomarkers. The comprehensive report features detailed evaluations of the technologies and business strategies of 60 companies, plus summaries of 9 companies currently using bead-based assays for diagnostics.
In addition, the report features a detailed, hierarchical market model. At the highest level, the market is divided into three application areas: (1) drug target and biomarker identification and validation, (2) drug development, and (3) clinical trials and diagnostics. At the next level, the market is divided by biochip dimension: 2-dimensional planar arrays and 3-dimensional bead arrays. The next level is the type of biochip: capture and interaction. At the lowest level: hardware and biochips.
Furthermore, to enable readers to take full advantage of the expertise of the authors, the report comes with one free hour of consulting. Steven Bodovitz and Jutta Bachmann will be available for conference calls to discuss market drivers, company evaluations, and financial projections.
To order a copy of the report, please (1) visit
www.bioperspectives.com or www.jbachmann-consulting.com, (2) call BioPerspectives in the United States at 415-336-2700 or Bachmann Consulting in Norway at +47-6691-2809, or (3) email us at either bodovitzs@bioperspectives.com or info@jutta-bachmann.com.
About the Authors:
Steven Bodovitz is a Principal and Co-Founder of BioPerspectives (formerly BioInsights). He is an international authority on protein biochips, protein biomarkers, and proteomics. He is the lead advisor for IBC’s Chips to Hits conference and will be delivering the opening presentation in September 2004; he has published articles in Trends in Biotechnology, Drug Discovery Today, and Drug Discovery World in the last year alone; he chaired the plenary session of IBC’s Proteomics and the Proteome conference in Basel, Switzerland in June 2003; and he has also presented at biotechnology conferences in England, Germany, Italy, The Netherlands, California, and Japan. Moreover, Dr. Bodovitz has been quoted in The Economist and Nature Biotechnology.
Jutta Bachmann is Principal and founder of Bachmann Consulting. She has been an advisor for IBC's recent Eurobiochips, as well as other microarray-related conferences organized by CHI and IBC. She chaired theProtein Microarray session of last year's Chips to Hits in Boston, the Advancements of Protein Arrays session of last year's EuroBiochips in London, the Advances in Hybridization and Reliability session at the Lab-on-a-chip and Microarrays conference in Zurich in 2003, and the Bioinformatics session of the BioDigital conference in Freiburg, Germany in 2002. She is the project manager of the
www.biochipnet.de Internet portal as well as of a recently launched portal on regenerative biology (www.regenerationnet.com). She has published articles in Trends in Genetics, Drug Discovery Today, Future Drug Discovery, Trends in Drug Discovery as well as co-authored a book on MHC ligands. In addition, she has written, "Der Information Broker," which provides insights into the work of an information broker as well as details of databases and information research.Thomas Joos is head of the biochemistry department of the NMI Natural and Medical Sciences Institute at the University of Tübingen and scientific advisor of BioChipNet. Dr. Joos has been with the NMI since 1998, where he has been responsible for DNA and protein biochip technology. Thomas Joos is a member of the editorial board of Target and Expert Review of Proteomics, the German Society for Proteomic Research (Deutsche Gesellschaft für Proteomforschung), and the Scientific Committee of the DECHEMA "Statusseminar Chip Technology". Thomas Joos is an invited speaker, advisor, and chairman at major international biochip conferences. He has published numerous papers, including recent articles in Combinatorial Chemistry & High Throughput Screening, Trends in Biotechnology, Clinical Chemistry, Proteomics, and Drug Discovery Today.